Institutional Investors Own a Significant Stake of 50% in Compass Therapeutics, Inc. (NASDAQ:CMPX)
Leerink Partners Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Cuts Target Price to $5
Compass Therapeutics Strategy Pivot and Outperform Rating Amidst Clinical Setbacks
Stifel Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $10
Compass Therapeutics (CMPX) Gets a Buy From Stifel Nicolaus
Express News | Compass Therapeutics Inc. : Leerink Partners Cuts Target Price to $5 From $10
Compass Therapeutics Shares Rise After Q2 Results
Buy Rating Affirmed: Compass Therapeutics' Promising Pipeline and Prudent Financial Outlook
Compass Therapeutics | 10-Q: Q2 2024 Earnings Report
Express News | Compass Therapeutics Q2 Income From Operations USD -15.045 Million
Express News | Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update
Express News | Compass Therapeutics Q2 Net Income USD -13.076 Million
Express News | Compass Therapeutics Q2 Basic EPS USD -0.1
Express News | Compass Therapeutics Q2 Operating Expenses USD 15.895 Million
Catalyst Watch: Eyes on Walmart Earnings, the July CPI Print, and 13F Filings
Wedbush Reiterates Outperform on Compass Therapeutics, Maintains $8 Price Target
Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
Buy Rating Affirmed on Compass Therapeutics as Clinical Trials of CTX-009 Show Promise in Biliary Tract Cancer Treatment
Express News | Compass Therapeutics Completes Patient Enrollment in Companion-002, a Randomized Study of Ctx-009 in Combination With Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer
Here's Why We're Not Too Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Situation
No Data